News Posts List
FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ERTM (amantadine) extended-release tablets
Bridgewater, NJ – February 19, 2018 – Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous system (CNS) treatments utilizing its proprietary osmotic drug delivery platform, announced today that the U.S. Food and Drug Administration (FDA) has approved OSMOLEX ERTM, an amantadine extended release tablet, for the treatment of Parkinson's disease and for the treatment of drug-induced extrapyramidal reactions in adult patients. Extrapyramidal symptoms are known side effects of many common medications.
By Jeremy Levin February 14, 2018 The opioid epidemic is the worst public health crisis in a generation. Millions of individuals, families and communities have been impacted. We need new ideas to help strengthen the calls for action by policymakers and health experts to address this growing national emergency. Fortunately, if we are willing to learn from past experiences, we can first blunt and then end this crisis. In the 1980s, the United States faced the devastating health crisis of HIV/AIDS. But by marshaling resources and ingenuity, the nation contained and rolled back the worst effects of this crisis. Those who lived during that period will remember the pain and fear felt by so many as reports of this deadly virus surfaced in one community after another. America’s biopharmaceutical community went to work. Joined by patient advocates, as well as researchers in university laboratories supported by partners at the state and federal levels, we embarked on a determined search for a cure.
Targeting Chronic Hepatitis B Infections Affecting More Than 240 Million People Worldwide GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with CaroGen Corporation on the development of a combination immunotherapy treatment for chronic hepatitis B virus (HBV) infection.
ATLANTA—Researchers have developed a universal vaccine to combat influenza A viruses that produces long-lasting immunity in mice and protects them against the limitations of seasonal flu vaccines, according to a study led by Georgia State University. Influenza, a contagious respiratory illness that infects the nose, throat and lungs, is among the leading causes of death in the United States, according to the Centers for Disease Control and Prevention (CDC). The CDC estimates influenza has resulted in between 12,000 and 56,000 deaths annually in the U.S. since 2010.
Norcross, Georgia – January 16, 2018 – Immucor, Inc., a global leader in transfusion and transplantation diagnostics and a portfolio company of global alternative asset firm TPG, today announced the appointment of Avi Pelossof as President and Chief Executive Officer, effective immediately. Pelossof succeeds CEO Jeffrey R. Binder (“Jeff”), who retains his role as Chairman of the Immucor Board of Directors.
Mike Cassidy, president and CEO of the Georgia Research Alliance since 2000, will be stepping down by the end of the year. The Georgia Research Alliance with its high-powered public-private board has led the state’s technology and innovation efforts since its founding in 1990. Cassidy joined the organization in 1993 as its fourth staff member. “I will have been there 25 years this May. I will be 65 in November. And we will have a new governor next January,” Cassidy said in an interview. “All those forces converged, and I thought it would be a good time for a change in leadership.”
ATLANTA—The Center for Neuroinflammation and Cardiometabolic Diseases, a research center focused on inflammation in the brain and how it may contribute to a number of serious health conditions, has been introduced at Georgia State University.
INDIANAPOLIS, Jan. 3, 2018 /PRNewswire/ -- Performance Validation (PV), a nationwide leader in providing commissioning, qualification, validation, and quality services to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce the company has established an Employee Stock Ownership Plan (ESOP), becoming a 100% employee owned company.
Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Prep
ATLANTA, GA – Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for rare inflammatory diseases, today announced the successful completion of a Series E financing led by Invus. Additional investors in the financing include Domain Associates, Lumira Capital, Masters Capital Management, RMI Partners and the Georgia Research Alliance Venture Fund. In conjunction with the financing, Khalil Barrage, Managing Director at Invus, will join Celtaxsys’ board of directors.
Dubai, January 04, 2018: Pure Health Medical Supplies and Immucor Inc. have signed a five-year exclusive distribution agreement for theUAE.
|Neon CRM by Neon One|